tirzepatide hfpef trial In pts wiht and obesity, (Mounjaro®) significantly reduces HF hospitalization, diuretic intensification, or CV death by 38% vs placebo in SUMMIT https://t.co/8ZHm4gySiL Reaching the SUMMIT? Benefits and

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

But did you know other, similar drugs are in development

Keywords: body weight, glycated hemoglobin (HbA 1c ), efficacy, glucagon-like peptide-1 receptor agonist (GLP-1RA), oral, semaglutide, subcutaneous, type 2 diabetes Introduction Evidence from trials and real-world studies in patients with type 2 diabetes (T2D) indicates that the risk of complications may be reduced by providing sustained glycemic control and that near-normal glycated hemoglobin (HbA 1c ) levels should be achieved as early as possible in the T2D trajectory (1, 2)

This trial provides significant evidence supporting the efficacy of injection in achieving effective weight loss in individuals who are overweight or obese with and without type 2 diabetes

C.FloresG.QuirarteG